Icatibanto Exeltis (Icatibant)

Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By inhibiting this pathway, the drug reduces the swelling and pain that characterize hereditary angioedema attacks.

The dosage and administration schedule for Icatibanto Exeltis are determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of the HAE attack, and individual response. The prescriber will provide specific instructions.

Safety data for icatibant in pregnancy and lactation are limited, and the pregnancy category is unknown. Use only if the potential benefit justifies the potential risk to the fetus or infant, and discuss any concerns with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Icatibant is a selective B2‑receptor antagonist administered subcutaneously, offering rapid symptom relief. Alternative therapies include C1‑esterase inhibitor concentrates (intravenous) and newer monoclonal antibodies targeting kallikrein. Choice depends on factors such as route preference, speed of onset, and individual patient response.

Icatibanto Exeltis should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional or a trained patient can administer the dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and the prescriber’s instructions.

Serious adverse events include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of angioedema unrelated to hereditary angioedema. Patients should be monitored closely after injection, and any signs of severe allergic reaction require immediate medical attention.

Icatibanto Exeltis is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients, and in patients with documented deficiency of the bradykinin B2 receptor. Caution is also advised for patients with severe renal or hepatic impairment.